Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its potential impact on metabolic health and the competitive landscape against Novo Nordisk.
Recent developments in weight-loss medications highlight the potential of amylin-based drugs, which may offer effective weight management with fewer gastrointestinal side effects…
Eli Lilly's GLP-1 drug retatrutide has demonstrated remarkable efficacy in aiding individuals with Type 2 diabetes to lose up to 60 pounds, or about 23% of their body weight, acco…
Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
Numerous lawsuits have been initiated in the United States against companies producing GLP-1 medications, such as Ozempic and Mounjaro, claiming these drugs may lead to a rare eye…
The experimental gene-editing drug VERVE-102, developed by Eli Lilly, has demonstrated the potential to reduce LDL cholesterol levels by up to 62% in early trials. This therapy ai…
A recent trial failure by Novartis has adversely affected the entire Lp(a) drug class, with Amgen experiencing a significant drop in stock value despite its own positive trial res…
The FDA has granted approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in individuals with type 2 diabetes, marking a significant development in diabetes management…
Eli Lilly has reported a significant revenue increase of 47% in the second quarter, reaching $22.97 billion, despite a decline in employer insurance coverage for GLP-1 weight-loss…
The FDA has approved Eli Lilly's medication Mounjaro for reducing the risk of heart events in individuals with Type 2 diabetes. This approval adds to the drug's existing use for b…
As the popularity of weight-loss drugs like GLP-1 receptor agonists grows, a black market for the unapproved drug retatrutide has emerged, alarming health experts. Developed by El…
As hospitals report an increase in patients experiencing side effects from the unapproved weight-loss drug Retatrutide, health experts are raising alarms about its use. Despite no…
In a bold new initiative, the administration seeks to reassure investors that while psychedelic research faces hurdles, their bank accounts will float high above any mental health…
Wall Street's main indices experienced gains, led by healthcare stocks hitting record highs and easing oil prices. The Dow Jones rose by 0.97%, while the S&P 500 and Nasdaq also s…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…